

Special Issue

Genomics- and Proteomics-Driven Discoveries on Cancer Metastasis: Impacts on Therapeutics and Diagnostics

Message from the Guest Editor

Metastasis occurs when cancer cells spread from its site of origin (the primary tumor) to other organs. The metastatic process is a manifestation of the confluence of various molecular events (mutations, epigenetic changes, transcriptional changes, post-translational modifications, and other regulatory mechanisms) that allow tumor cells to escape and invade other organs via the bloodstream. It is a sign that cancer has reached a malignant, difficult-to-treat stage. Our understanding of cancer metastasis has considerably advanced during the last 10–15 years because of the widespread use of modern genomic and proteomic tools. The comparative molecular profiling of metastatic spread, primary tumors, normal tissues, and circulating tumor cells, along with the use of animal models, have immensely contributed to our understanding of the biology (and led to new hypotheses) behind the metastatic process. We are hopeful that knowledge gained from these studies may ultimately lead to the improvement of clinical management of cancer.

Guest Editor

Dr. Manny D. Bacolod

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA

Deadline for manuscript submissions

closed (31 May 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/59432

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)